NCT01904539View on ClinicalTrials.gov

Hepatic Impairment Trial of Obeticholic Acid

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Hepatic Impairment
Interventions
DRUG

obeticholic acid 10 mg

Single dose OCA 10mg in each arm

Trial Locations (2)

32809

Orlando Clinical Research Center, Orlando

33014

Clinical Pharmacology of Miami, Inc., Miami

Sponsors
All Listed Sponsors
lead

Intercept Pharmaceuticals

INDUSTRY